Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 9NIH 4NETWORK 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Multiple Myeloma 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Neoplasms, Plasma Cell 14Lymphoma 14Leukemia 13Burkitt Lymphoma 10Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 5HIV Infections 5Brain Neoplasms 5Acquired Immunodeficiency Syndrome 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Leukemia, Biphenotypic, Acute 4Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Rectal Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Down Syndrome 2Dendritic Cell Sarcoma, Interdigitating 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Leucovorin 6Cyclophosphamide 6Vincristine 5Methotrexate 5Cytarabine 5Mercaptopurine 4Dexamethasone 4Daunorubicin 4Thioguanine 3Specimen Handling 3Prednisolone 3Methylprednisolone 3Hydrocortisone 3Doxorubicin 3Asparaginase 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2blinatumomab 2azathiopurine 2auricularum 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Carboplatin 2Calcium Dobesilate 2venetoclax 1uproleselan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Leukemia, Biphenotypic, Acute × Dexamethasone × Clear all
NCT06317662 2026-06-03

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
153 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT02828358 2025-02-27

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

National Cancer Institute (NCI)

Phase 2 Completed
78 enrolled 15 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT00061945 2022-05-03

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
302 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00003728 2011-01-21

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 3 Unknown
1,500 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡